RxDoctor Payments Data

Chadi Dib, MD

Interventional Cardiology · Plano, TXNPI 1790903581

Payments from drug & device makers

$202,375in general payments, 2019–2025

Across 664 payments — averaging $304.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Endovascular Engineering Inc.$119K
  • Medtronic$33K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$20K
  • Boston Scientific$12K
  • Philips North America LLC$4K
  • Abbott$2K
  • plus $12K from 47 others

What the payments were for

  • Consulting fees$10,06312%
  • Speaking & faculty fees$47,25056%
  • Travel & lodging$5,0876%
  • Food & beverage$21,92026%
  • Education$150%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$202,375 in reported general payments places this provider in the 90th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$458,685
Medicare patients
1,752
Services billed
14,403

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban169$198,621
Repatha SureclickEvolocumab118$129,421
XareltoRivaroxaban101$127,592
EntrestoSacubitril/Valsartan36$42,455
Praluent PenAlirocumab36$26,080
NexletolBempedoic Acid22$24,571
Repatha SyringeEvolocumab15$18,275
EdarbiAzilsartan Medoxomil29$15,688
NexlizetBempedoic Acid/Ezetimibe11$9,695
Ezetimibe318$8,094
Rosuvastatin Calcium443$7,048
Metoprolol Succinate222$3,933
LivaloPitavastatin Calcium11$3,543
Nifedipine ErNifedipine115$3,495
ClopidogrelClopidogrel Bisulfate237$3,344

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$86$198,621169 claims
Johnson & JohnsonXarelto$699$127,592101 claims
NovartisEntresto$1,305$42,45536 claims
Esperion Therapeutics, Inc.Nexletol, Nexlizet$46$34,26533 claims
Arbor Pharmaceuticals, Inc.Edarbi$42$15,68829 claims
Kowa Pharmaceuticals America, Inc.Livalo$12$3,54311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in Plano

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →